News

Public · Published

ArriVent BioPharma, Inc. Stock 12‑Month Price Target Raised to $24, Implies 14% Upside

The average 12-month price target for ArriVent BioPharma stock rose from $22.91 to $24 across 11 analysts, with forecasts ranging from $15 to $30. Based on the Oct. 23 closing price, the new target implies about 14% potential upside.

Published:

Updated:

What happened

The average 12-month price target for ArriVent BioPharma stock rose from $22.91 to $24 across 11 analysts, with forecasts ranging from $15 to $30. Based on the Oct. 23 closing price, the new target implies about 14% potential upside.

Confirmed

Global impact / market context

A higher average target means analysts on balance expect more gains ahead, which can draw buyer interest and support the share price. The all-Buy consensus shows strong confidence, but targets still range widely from $15 to $30, so views differ.

Analyst inference

Analyst targets are average expectations, not guarantees, and can change quickly after trial results or financial reports. The 14% upside figure depends on the Oct. 23 closing price, so the implied gain shifts as the stock moves.

Analyst inference

What to watch

  1. Watch whether the average target keeps rising, since it moved from $22.91 to $24, and whether the $15 to $30 range narrows as analysts update their views. Confirmed
  2. Watch for new analyst notes that change ratings away from the current all-Buy consensus of 12 Buys, 0 Holds and 0 Sells, as any downgrade would shift the average target. Proposed
  3. Watch company updates such as trial results or financial reports, which could prompt analysts to revise targets and test whether the implied 14% upside holds. Analyst inference

Evidence

  • Original source link unavailable